Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Pamiparib + Tislelizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pamiparib | BGB-290|BGB290 | PARP Inhibitor (Pan) 21 | Pamiparib (BGB-290) inhibits PARP1 and PARP2, potentially resulting in increased sensitivity to DNA damaging agents (AACR; 2015. Abstract nr 1651, PMID: 32652442). | |
Tislelizumab | BGB-A317 | Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 68 | Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Advanced Solid Tumor | not applicable | Pamiparib + Tislelizumab | Phase Ib/II | Actionable | In a Phase Ib trial, the combination therapy of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) in patients with advanced solid tumors was well-tolerated and resulted in an objective response in 20% (10/49), with two complete responses and eight partial responses, stable disease in 32% (16/49), a disease control rate of 53% (26/49), and a clinical benefit of 39% (PMID: 31378459; NCT02660034). | 31378459 |
Unknown unknown | pancreatic cancer | not applicable | Pamiparib + Tislelizumab | Case Reports/Case Series | Actionable | In a Phase Ib trial, the combination therapy of of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) in patients with pancreatic cancer resulted in one partial response and stable disease for greater than 6 months in two patients (J Clin Oncol 35, 2017 (suppl; abstr 3013)). | detail... |
Unknown unknown | ovarian cancer | not applicable | Pamiparib + Tislelizumab | Case Reports/Case Series | Actionable | In a Phase Ib trial, the combination therapy of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) in ovarian cancer patients resulted in a clinical response in 26% (9/34) with two complete responses and seven partial responses (PMID: 31378459; NCT02660034). | 31378459 |
Unknown unknown | uterine cancer | not applicable | Pamiparib + Tislelizumab | Case Reports/Case Series | Actionable | In a Phase Ib trial, the combination therapy of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) resulted in a partial response in a patient with uterine cancer (J Clin Oncol 35, 2017 (suppl; abstr 3013)). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | 5 |
NCT04164199 | Phase III | Pamiparib + Tislelizumab Pemetrexed Disodium + Tislelizumab Tislelizumab Capecitabine + Tislelizumab Pamiparib | Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies | Enrolling by invitation | USA | 4 |